01036nas a2200121   4500000000100000008004100001100001700042700001200059245010600071300000800177520071500185022001400900       2015                            d1 aPechalrieu D1 aLopez M00aCompounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).  a1-73 a<p>Tuberculosis is one of the main causes of mortality with 1.5 million deaths a year worldwide. The growing emergence of multi- and extremely resistant strains highlights the urgent need of novel antibiotic strategies. Ethionamide, interfering with the mycobacterial membrane biosynthesis, is used in second-line treatment. This molecule is a prodrug, which requires activation by EthA. The patent described in this evaluation (WO2014049107A1) claimed a new family of molecules and their use as antibiotic treatment against mycobacteria such as Mycobacterium tuberculosis, M. leprae and atypical mycobacteria, either as a single active agent or in combination with antibiotics activable by EthA pathway.</p>
  a1744-7674